¼¼°èÀÇ Ã¢»ó ÇǺ¹Àç ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 50¾ï 5,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ°í 2029³â±îÁö 60¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖÀ¸¸ç, ¿¹Ãø ±â°£(2024-2029³â) Áß 3.61%ÀÇ CAGR·Î ¼ºÀåÇÕ´Ï´Ù.
COVID-19´Â ÀÇ·á »ê¾÷ Àü¹Ý¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ´ëºÎºÐÀÇ »óó´Â ±³Åë»ç°í¿Í ±³Åë»ç°í·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. À̰ÍÀÌ ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ¿äÀÎÀÌ µÇ¾ú½À´Ï´Ù. Àü¿°º´ È®»ê Ãʱ⿡ Àü ¼¼°è°¡ ºÀ¼âµÇ°í ´ëÁß±³ÅëÀÌ Áß´ÜµÇ¸é¼ »ç°í¿Í ºÎ»óÀº ÈξÀ ÁÙ¾îµé¾ú½À´Ï´Ù. 2021³â ¹ßÇ¥µÈ 'SARS-CoV-2 ÆÒµ¥¹ÍÀÌ »çÁö¸¦ À§ÇùÇÏ´Â ¸¸¼º ÇãÇ÷°ú »óó °ü¸®¿¡ ¹ÌÄ¡´Â ¿µÇâ'À̶ó´Â Á¦¸ñÀÇ ³í¹®¿¡ µû¸£¸é »çÁö¸¦ À§ÇùÇÏ´Â ¸¸¼º ÇãÇ÷°ú °°Àº ½É°¢ÇÑ °æ¿ì¸¦ Á¦¿ÜÇϰí, »óó Ä¡·áÀÇ ÆÐ·¯´ÙÀÓ º¯È´Â ȯÀÚ¸¦ Áý¿¡ ¸Ó¹°°Ô ÇÏ°í º´¿ø ¹æ¹® ¹× ÀÔ¿ø Ƚ¼ö¸¦ ÁÙÀ̱â À§ÇÑ ¿ø°ÝÀÇ·á ¹× ÀçÅÃÄ¡·á Á¢±Ù ¹æ½Ä¿¡ ´ëÇÑ Á¢±Ù ¹æ½ÄÀÔ´Ï´Ù. µû¶ó¼ À§ÀÇ ¿äÀÎÀº COVID-19°¡ â»ó ÇǺ¹Àç ½ÃÀå¿¡ ´«¿¡ ¶ç´Â ¿µÇâÀ» ¹ÌÃÆÀ½À» º¸¿©ÁÝ´Ï´Ù.
â»ó ÇǺ¹Àç ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ¸¸¼º »óó, ´ç´¢º´¼º ±Ë¾ç ¹ß»ý·ü Áõ°¡, Àü ¼¼°è ¼ö¼ú °Ç¼ö Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ±¹Á¦´ç´¢º´¿¬¸Í(IDF)ÀÇ 2022³â ÃֽŠÁ¤º¸¿¡ µû¸£¸é ¾à 5¾ï 3,700¸¸ ¸íÀÇ ¼ºÀÎ(20-79¼¼)ÀÌ ´ç´¢º´À» ¾Î°í ÀÖ½À´Ï´Ù. ´ç´¢º´ ȯÀÚ ¼ö´Â 2030³â±îÁö 6¾ï 4,300¸¸ ¸í, 2045³â±îÁö 7¾ï 8,300¸¸ ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ IDF 2021 º¸°í¼¿¡ µû¸£¸é Àü ¼¼°è¿¡¼ 4,000¸¸ ¸í¿¡¼ 6,000¸¸ ¸íÀÌ ´ç´¢º´¼º Á·ºÎ±Ë¾çÀ» ¾Î°í ÀÖ½À´Ï´Ù. °á°úÀûÀ¸·Î ´ç´¢º´¼º Á·ºÎ±Ë¾ç À¯º´·ü Áõ°¡·Î ÀÎÇØ ½ÃÀåÀÌ ¼ºÀåÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù.
¸¸¼º »óó´Â °¨¿°, ±Ë¾ç Çü¼º, Ç÷¾× °ø±Þ ºÎÁ·°ú °°Àº ÇÕº´ÁõÀ» À¯¹ßÇÏ°í »óóÀÇ Ä¡À¯ ±â°£ÀÌ ±æ¾îÁý´Ï´Ù. °¡Àå ÈçÇÑ ¸¸¼º »óó¿¡´Â Á¤¸Æ ±Ë¾ç, ´ç´¢º´¼º Á·ºÎ ±Ë¾ç, ¿åâ µîÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¤ºÎÀÇ ±¸»ó, ÀÎ½Ä °³¼± ÇÁ·Î±×·¥ ¹× Á¦Ç° Ãâ½Ã´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î Wounds Australia´Â 2021³â »óó ÀÎ½Ä ÁÖ°£(WAW21) Ä·ÆäÀÎÀ» ÅëÇØ ¸¸¼º »óó ÇÕº´Áõ¿¡ ´ëÇÑ ±³À°À» ½ÃÇàÇϰí À§Ç輺, °æ°í ½ÅÈ£ ¹× Ä¡·á¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̱â À§ÇØ ³ë·ÂÇß½À´Ï´Ù. 2022³â Ä·ÆäÀÎÀº »óó·Î °íÅë¹Þ´Â »ç¶÷µéÀ» À§ÇÑ ±¹°¡Àû º¯È¸¦ ÃËÁøÇÏ´Â µ¥ ÇÊ¿äÇÑ ¼Ö·ç¼Ç¿¡ ÃÊÁ¡À» ¸ÂÃè½À´Ï´Ù.
»ó±â ¿äÀο¡ µû¶ó â»ó ÇǺ¹Àç ½ÃÀåÀº ¿¹Ãø ±â°£ Áß ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ³ôÀº ºñ¿ë°ú °í±Þ â»ó ÇǺ¹Àç Á¦Ç°¿¡ ´ëÇÑ ÀÎ½Ä ºÎÁ·Àº ½ÃÀå ¼ºÀåÀ» ¾ïÁ¦Çϰí ÀÖ½À´Ï´Ù.
°í±Þ â»ó ÇǺ¹Àç´Â Ä¡À¯¸¦ ÃËÁøÇϱâ À§ÇØ »óóÀÇ ¼öºÐÀ» À¯ÁöÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß°í ÀÖÀ¸¸ç ÀϹÝÀûÀ¸·Î ÀÇ»ç ¶Ç´Â º´¿ø ¹æ¹® ÈÄ ÀÓ»óÀǰ¡ ó¹æÇÕ´Ï´Ù. °í±Þ â»ó ÇǺ¹Àç¿¡´Â Çʸ§, Æû, ÇÏÀ̵å·Î°Ö, ÇÏÀ̵å·ÎÄÝ·ÎÀ̵å, Äݶó°Õ, Á¢ÃË Ãþ µîÀÌ Æ÷ÇԵ˴ϴÙ. ´ç´¢º´¼º Á·ºÎ ±Ë¾çÀÇ À¯º´·ü Áõ°¡¿Í °°Àº ¿äÀÎÀº ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÀÌÀ¯ Áß ÇϳªÀÔ´Ï´Ù. IDFÀÇ 2020³â ÃֽŠÁ¤º¸¿¡ µû¸£¸é ´ç´¢º´¼º Á·ºÎ±Ë¾çÀº Àü ¼¼°è¿¡¼ 4,000¸¸ ¸í¿¡¼ 6,000¸¸ ¸íÀÇ ´ç´¢º´ ȯÀÚ°¡ ¾Î°í ÀÖ´Ù°í ÇÕ´Ï´Ù.
¶ÇÇÑ ´Ù¾çÇÑ Á¦Ç°À» »ç¿ëÇÒ ¼ö ÀÖÀ¸¸ç, ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¸Àç¿Í ÷´Ü â»ó ÇǺ¹Àç Á¦Ç°À» ¹ßÀü½Ã۱â À§ÇÑ ¿¬±¸°³¹ß Ȱµ¿µµ Áß¿äÇÕ´Ï´Ù. ¿¹¸¦ µé¾î 2022³â¿¡ ¹ßÇ¥µÈ 'L-¸ÞġƮ¶õÆû: »õ·Î¿î »óó Ä¡·á Á¦Ç°ÀÇ Æò°¡'¶ó´Â Á¦¸ñÀÇ ³í¹®¿¡ µû¸£¸é ÀÇ·á¿ë L-¸ÞġƮ¶õ ²ÜÀº °·ÂÇÑ Ç×±Õ ¹× »óó Ä¡À¯ È¿°ú°¡ ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. L-¸ÞġƮ¶õ ÆûÀº L-¸ÞġƮ¶õ ¼ÒÇÁÆ®ÀÇ ÀÌ·¯ÇÑ Æ¯¼º°ú Æû µå·¹½Ì ±â¼úÀ» °áÇÕÇÑ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ ³ëÀÎ Àα¸ Áõ°¡, ½ºÆ÷Ã÷ ºÎ»ó Áõ°¡ ¹× ±×¿¡ µû¸¥ ´ç´¢º´ÀÇ À§ÇèÀº ¿¹Ãø ±â°£ Áß ºÎ¹®ÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î Á¸ ȩŲ½º ´ëÇÐÀÇ 2022³â ½ºÆ÷Ã÷ ºÎ»ó Åë°è¿¡ µû¸£¸é ¹Ì±¹¿¡¼ ¾à 3,000¸¸ ¸íÀÇ ¾î¸°ÀÌ¿Í Ã»¼Ò³âÀÌ Á¶Á÷ÈµÈ ½ºÆ÷Ã÷¿¡ Âü¿©Çϰí ÀÖÀ¸¸ç, ¸Å³â 350¸¸ °Ç ÀÌ»óÀÇ ºÎ»óÀÌ ¹ß»ýÇÑ´Ù°í ÇÕ´Ï´Ù. ºÎ»ó »ç°Ç Áõ°¡·Î ÀÎÇØ â»ó ÇǺ¹ÀçÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÏ¿© ½ÃÀå ¼ºÀåÀ¸·Î À̾îÁ³½À´Ï´Ù. ¶ÇÇÑ °æÀï»çÀÇ Á¸Àç, ÇÕº´, Àμö ¹× Á¦Ç° Ãâ½Ã´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÕ´Ï´Ù. ¿¹¸¦ µé¾î 2020³â 4¿ù ¼¼°è ÀÇ·á ±â¼ú ±â¾÷ÀÎ Convatec Group Plc´Â ConvatecÀÌ ÆÇ¸ÅÇÏ´Â »õ·Î¿î ÃÊÈí¼ö¼º µå·¹½ÌÀÎ ConvaMaxÀÇ Ãâ½Ã¸¦ ¹ßÇ¥Çß½À´Ï´Ù.
µû¶ó¼ À§ÀÇ »ç½Ç¿¡ µû¸£¸é ÷´Ü â»ó ÇǺ¹Àç ºÎ¹®Àº ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù.
ºÏ¹Ì´Â ÀÇ·á ÀÎÇÁ¶ó°¡ Àß °®Ãß¾îÁ® ÀÖ°í ¼ö¼ú °Ç¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó â»ó ÇǺ¹Àç ½ÃÀå¿¡¼ Å« ºñÁßÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ±¹³», ƯÈ÷ ¹Ì±¹ÀÇ ´ç´¢º´ Àα¸°¡ ¸¹´Ù´Â °ÍÀº ´ç´¢º´¼º ±Ë¾ç »ç·Ê°¡ Áõ°¡ÇÒ ¼ö ÀÖ´Ù´Â °ÍÀ» ÀǹÌÇÕ´Ï´Ù. ¿¹¸¦ µé¾î ±¹Á¦ ´ç´¢º´ ¿¬¸Í¿¡ µû¸£¸é ¹Ì±¹Àº IDF NAC Áö¿ª 23°³±¹ Áß ÇϳªÀÔ´Ï´Ù. Àü ¼¼°è¿¡¼ 5¾ï 3,700¸¸ ¸íÀÌ ´ç´¢º´À» ¾Î°í ÀÖÀ¸¸ç, NAC Áö¿ª¿¡¼´Â 5,100¸¸ ¸í ÀÌ»óÀÌ ´ç´¢º´À» ¾Î°í ÀÖÀ¸¸ç, ÀÌ ¼öÄ¡´Â 2045³â±îÁö 6,300¸¸ ¸íÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
°æÀï»çÀÇ Á¸Àç, Àμö, ÇÕº´Àº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÕ´Ï´Ù. ¿¹¸¦ µé¾î 2022³â 3¿ù Å׳׽ÃÁÖ¿¡ º»»ç¸¦ µÐ Triad Life Sciences Inc°¡ Convatec Group¿¡ ÀμöµÇ¾ú½À´Ï´Ù. TriadÀÇ ÇöÀç Æ÷Æ®Æú¸®¿À¿Í Á¦Ç° ÆÄÀÌÇÁ¶óÀÎÀº ConvatecÀÇ Advanced Wound Care(AWC) »ç¾÷ºÎ·Î ÀÌÀüµÇ¾î Convatec Advanced Tissue Technologies·Î ¾Ë·ÁÁö°Ô µË´Ï´Ù.
À§ ¿äÀο¡ µû¸£¸é ºÏ¹Ì´Â ¿¹Ãø ±â°£ Áß Á¶»ç ´ë»ó ½ÃÀå¿¡¼ ³ôÀº ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
Á¶»çµÈ â»ó ÇǺ¹Àç ½ÃÀåÀº ¿©·¯ ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¸Àç·Î ÀÎÇØ Àû´çÈ÷ ÅëÇÕµÈ ½ÃÀåÀÔ´Ï´Ù. ½ÃÀå Âü¿©ÀÚµéÀº ½ÃÀå¿¡¼ »õ·Ó°í È¿À²ÀûÀÎ Á¦Ç°À» °³¹ßÇϱâ À§ÇØ ¿¬±¸°³¹ß¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå Âü¿©ÀÚ´Â 3M Company, ConvaTec Group PLC, DermaRite Industries LLC, DeRoyal Industries Inc. Corporation, Coloplast A/S, Medtronic plc, Molnlycke Health Care AB, Smith &Nephew plc µîÀÌ ÀÖ½À´Ï´Ù.
The Global Wound Dressings Market size is estimated at USD 5.05 billion in 2024, and is expected to reach USD 6.02 billion by 2029, growing at a CAGR of 3.61% during the forecast period (2024-2029).
COVID-19 had a significant impact on the overall healthcare industry. Road accidents and transportation injuries are responsible for most of the wounds. This served as the market's primary growth factor. There were far fewer accidents and injuries because of the global lockdown imposed during the early stages of the epidemic and the cancellation of public transportation. As per the article published in 2021 under the title 'The impact of the SARS-CoV-2 pandemic on the management of chronic limb-threatening ischemia and wound care', except in critical cases like chronic limb-threatening ischemia, there has been a paradigm change in wound care toward hybrid telemedicine and home healthcare approach to keep patients at home and decrease the amount of in-person clinic visits and hospitalizations. Hence, the factors mentioned above showed that COVID-19 had a notable impact on the wound dressings market.
The major factors for the growth of the wound dressings market include the rising incidences of chronic wounds, diabetic ulcers, and an increase in the volume of surgical procedures worldwide. For instance, as per the 2022 update from the International Diabetic Federation (IDF), approximately 537 million adults (20-79 years) are living with diabetes. The total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. Moreover, as per the IDF 2021 report, diabetic foot ulcers were affected by 40 to 60 million people globally. As a result, the market is likely to grow due to the increased prevalence of diabetic foot ulcers.
Chronic wounds lead to complications, such as infection, ulceration, and insufficient blood supply, thus, increasing the wound healing period. The most common chronic wounds include venous ulcers, diabetic foot ulcers, and pressure ulcers. Furthermore, government initiatives, awareness programs, and product launches boost market growth. For instance, Wounds Australia developed the Wound Awareness Week (WAW21) campaign in 2021 for the purpose of educating people regarding chronic wound complications and raising awareness of risks, warning signs, and treatments. In 2022 the campaign focused on the solutions needed to drive national change for those living with wounds.
As per the factors mentioned above, the wound dressings market is anticipated to witness growth over the forecast period. However high cost and lack of awareness about advanced wound dressing products restrain the market growth.
Advanced wound dressing focuses on keeping the wound hydrated to encourage healing and is generally prescribed by clinicians after a visit to the doctor or hospital. Advanced wound dressings include film, foam, hydrogel, hydrocolloid, collagen, and contact layers, among others. Factors such as the increased prevalence of diabetic foot ulcers are one of the major reasons behind the market growth. As per the 2020 update from IDF, diabetic foot ulcers affect 40 to 60 million people with diabetes globally.
Moreover, the availability of a wide range of products and the presence of key market players and R&D activities to advance the products in Advanced wound dressings. For instance, as per the article published in 2022, under the title 'L-Mesitran Foam: Evaluation of a New Wound Care Product', the study showed that the medical-grade honey of L-Mesitran has strong antimicrobial and wound healing activities. L-Mesitran Foam combines these properties of L-Mesitran Soft with the technology of foam dressings. Furthermore, the growing geriatric population, rising number of sports injuries, and associated risk of diabetes are projected to fuel the segment growth over the forecast period. For instance, as per the 2022 update from John Hopkins Sports Injury Statistics, in the United States, about 30 million children and teens participate in some form of organized sports, and more than 3.5 million injuries each year. Since increased injury cases lead to more adoption of wound dressing leading to market growth. Moreover, the presence of competitors, mergers, acquisitions, and product launches fuel the market growth. For instance, in April 2020, Convatec Group Plc, a global medical technology company, announced the launch of ConvaMax, a new superabsorber dressing distributed by Convatec.
Hence, as per the facts mentioned above, the advanced wound dressing segment is likely to boost market growth over the forecast period.
North America holds a major share in the wound dressings market, owing to the presence of better healthcare infrastructure and a rising number of surgical procedures in the region. The high number of diabetic populations in the country especially in the United States is indicating that there are chances of rising cases of diabetic ulcers. For instance, as per International Diabetes Federation, the United States of America is one of the 23 countries in the IDF NAC region. 537 million people have diabetes in the world and more than 51 million people in the NAC Region, this count is expected to rise to 63 million by 2045.
The presence of competitors, acquisitions, and mergers boost the market growth. For instance, in March 2022, Tennessee-based Triad Life Sciences Inc was acquired by Convatec Group. The Triad's current portfolio and product pipeline is transferred to Convatec's Advanced Wound Care (AWC) business and is likely to be known as Convatec Advanced Tissue Technologies.
As per the factors mentioned above, North America is expected to register a high growth rate for the studied market over the forecast period.
The Wound Dressings market studied is a moderately consolidated market owing to the presence of a few major market players. The market players are focusing on R&D to develop new and efficient products in the market. Some of the market players are 3M Company, ConvaTec Group PLC, DermaRite Industries LLC., DeRoyal Industries Inc., Hollister Incorporated, Integra LifeSciences Holdings Corporation, Coloplast A/S, Medtronic plc, Molnlycke Health Care AB, and Smith & Nephew plc